作者: M. Grilli , M. Pizzi , F. Goffi , M. Benarese , G. M. Gerardi
DOI: 10.1007/978-1-4615-5337-3_15
关键词:
摘要: The idea that inflammatory processes contribute to the pathology of neurodegenerative diseases and in particular Alzheimer’s disease (AD), has been supported by epidemiological clinical studies. Multiple retrospective analyses indicate patients receiving anti-inflammatory drugs or suffering from conditions which such are routinely used, have a decreased risk developing AD (see McGeer McGeer, 1995, as review). In preliminary double-blind trial, non steroidal drug (NSAID) indomethacin proven reduce progression cognitive decline (Rogers et al., 1993). Obviously, more comprehensive trials need be carried out, but future therapy holds great promise.